Lilly’s Oral Orforglipron Met Ph3 ATTAIN-1 & 2 Primary Endpoints in Obesity (Aug 2025)
Автор: BioSpark Group
Загружено: 2026-01-21
Просмотров: 17
Описание:
Eli Lilly just released top-line Phase 3 results for orforglipron, its highly anticipated oral GLP-1. Why did the stock plunge despite meeting primary endpoints? We invited Wei Wang (Associate Principal Scientist at Merck) to decode the data logic behind the ATTAIN-1 & 2 trials.
【Key Highlights】
1. ATTAIN Series Analysis: Efficacy differences in obesity with vs. without type 2 diabetes.
2. The Estimand Factor: Why "Efficacy" vs. "Treatment Regimen" estimands are critical for FDA success.
3. Competitor Showdown: Orforglipron vs. Novo Nordisk’s oral semaglutide—does the "no diet/exercise" requirement give Lilly the edge?
4. Market Sentiment: From a 40% single-day loss to a recovery in investor confidence.
Essential viewing for biotech professionals, researchers, and pharma investors.
#EliLilly #Orforglipron #GLP1 #Obesity #ClinicalTrials #Biostatistics #PharmaInvestment
BioSpark Group is a non-profit corporation registered in Massachusetts in the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation. http://biospark.org/
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
